Profits jump 20% at Irish arm of US biotech Regeneron
Regeneron's Irish arm saw a 20% profit increase to $4.91B in 2025, with revenues up 3% to $12.53B. The company paid $716.6M in taxes and $5.3B in dividends. Key drugs Dupixent, Eylea HD, and Libtayo showed strong sales growth. Manufacturing was briefly disrupted due to repairs.
How this was made

The 30-second read
Why it matters
The disclosed profit surge and dividend payouts provide fresh data for valuation models and may influence analyst forecasts.
Market read
First‑time release of Regeneron's Irish arm profit figures, indicating strong earnings momentum and cash generation.
What to watch
The $120 m Pillar Two tax increase and recent facility repairs could pressure margins despite higher revenue.
Background
Regeneron is a US‑listed biotech with a large manufacturing presence in Ireland, contributing the bulk of its global revenue.
Market effects
Biotech sector may benefit from demonstrated profitability of a major US multinational's Irish operations.
Irish corporate tax contributions rise, highlighting the country's role in pharma manufacturing.
Regeneron's strong earnings could lift sentiment for US biotech stocks globally.
Counterpoint
Profit growth may be offset by temporary production interruptions and higher tax liabilities, limiting upside.
Key entities
- companyRegeneron Pharmaceuticals Inc.
US biotech parent of the Irish arm.



